Added to YB: 2025-06-06
Pitch date: 2025-06-04
NVO [bullish]
Novo Nordisk A/S
-34%
current return
Author Info
FluentInQuality invests in high-quality businesses that generate steady and sustainable cashflows, proven track records, and the potential to act as a true compounding machines over the long run. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 479.40
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
growth
Best Buys For June: Novo Nordisk A/S
NVO: Mission-driven diabetes & obesity leader with 40%+ margins, 20+ years dividends. Semaglutide (Ozempic/Wegovy) leads $100B+ obesity market with first-mover advantage. Deep pipeline extends to cardiovascular, kidney, NASH & Alzheimer's. Global reach with tiered pricing. Robust FCF, low debt, steady buybacks, high ROIC.
Read full article (2 min)